Takeda Pharmaceutical Company Limited ("Takeda") and Natrogen Therapeutics International, Inc. ("Natrogen") jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis (UC).
"Today's announcement reinforces Takeda's continued commitment toward addressing the needs of patients with gastrointestinal diseases," said Asit Parikh, M.D., Ph.D., vice president, general medicine, Takeda. "Natura-alpha is a strategic fit with our gastrointestinal portfolio, which also includes vedolizumab, Takeda's investigational monoclonal antibody for the treatment of adults with moderately to severely active UC and Crohn's disease."
The principal activity of Natrogen Therapeutics International has been to develop Natura-alpha, a small molecule oral compound that has been the subject of a Phase 2 Clinical Trial exploring efficacy and safety in patients with ulcerative colitis.